Загрузка...
Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis
BACKGROUND/OBJECTIVES: Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild‐to‐moderate atopic dermatitis (AD). This pooled post hoc analysis of two phase 3 trials (NCT02118766, NCT02118792) assessed improvement and time to improvement in Investigator&#...
Сохранить в:
| Опубликовано в: : | Pediatr Dermatol |
|---|---|
| Главные авторы: | , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7756882/ https://ncbi.nlm.nih.gov/pubmed/32981097 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pde.14328 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|